Aug 12, 2025 • Zacks Commentary
NEUTRAL
Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus
IMVT reports a narrower Q1 loss, as spotlight remains on IMVT-1402's broad clinical potential across multiple indications.
Aug 11, 2025 • Motley Fool
NEUTRAL
Immunovant Posts 34% R&D Jump in Q1
Immunovant ( NASDAQ:IMVT ) , a clinical-stage biotechnology company focused on therapies for autoimmune conditions, reported results for the quarter ended June 30, 2025, on August 11, 2025. Net loss per common share ( GAAP ) was $0.71 in Q1 FY2026.
Jul 16, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
All You Need to Know About Immunovant ( IMVT ) Rating Upgrade to Buy
Immunovant (IMVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Jul 16, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Wall Street Analysts See a 137.68% Upside in Immunovant ( IMVT ) : Can the Stock Really Move This High?
The mean of analysts' price targets for Immunovant (IMVT) points to a 137.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Jun 18, 2025 • Benzinga
SOMEWHAT-BULLISH
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors - Avalo Therapeutics ( NASDAQ:AVTX )
WAYNE, Pa., June 18, 2025 ( GLOBE NEWSWIRE ) -- Avalo Therapeutics, Inc. AVTX, a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors.
Jun 02, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Immunovant ( IMVT ) Upgraded to Buy: What Does It Mean for the Stock?
Immunovant (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.